Félix Guerrero-Ramos, MD, PhD, FEBU, discusses key findings from the phase 3 POTOMAC trial and other studies of BCG/ICI combinations in high-risk NMIBC.
Evolving treatment paradigms in high-risk NMIBC
Bradley McGregor, MD, contextualizes recent data on emerging treatment regimens in high-risk, BCG-naïve NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
Beyond the clinic: Physician presence on social media
3
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
4
Study validates Decipher as a predictor of early biochemical recurrence in prostate cancer
5